You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for New Drug Application (NDA): 208411


✉ Email this page to a colleague

« Back to Dashboard


NDA 208411 describes NARCAN, which is a drug marketed by Adapt, Bristol Myers Squibb, and Emergent, and is included in five NDAs. It is available from five suppliers. Additional details are available on the NARCAN profile page.

The generic ingredient in NARCAN is naloxone hydrochloride. There are twelve drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.
Summary for 208411
Tradename:NARCAN
Applicant:Emergent
Ingredient:naloxone hydrochloride
Patents:0
Pharmacology for NDA: 208411
Mechanism of ActionOpioid Antagonists
Medical Subject Heading (MeSH) Categories for 208411
Narcotic Antagonists
Suppliers and Packaging for NDA: 208411
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NARCAN naloxone hydrochloride SPRAY, METERED;NASAL 208411 NDA A-S Medication Solutions 50090-2422 50090-2422-0 2 VIAL, SINGLE-DOSE in 1 PACKAGE (50090-2422-0) / .1 mL in 1 VIAL, SINGLE-DOSE
NARCAN naloxone hydrochloride SPRAY, METERED;NASAL 208411 NDA AUTHORIZED GENERIC A-S Medication Solutions 50090-5908 50090-5908-0 2 VIAL, SINGLE-DOSE in 1 CARTON (50090-5908-0) / .1 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:OTCDosage:SPRAY, METERED;NASALStrength4MG/SPRAY
Approval Date:Nov 18, 2015TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:SPRAY, METERED;NASALStrength2MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date:Jan 24, 2017TE:RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links